Since then, additional agents have secured tumor-agnostic FDA indications, including targeted therapies for NTRK gene fusions, BRAF V600E mutations, RET fusions, as well as treatments based on high tumor mutational burden (TMB-H) or HER2 overexpression (Table 2) [79,80]. This evidence concerns the gene ERBB2 and neoplasm.